United Therapeutics ( UTHR) was among the best-performing health-related stocks Monday, with shares rising 10% after the biotechnology company posted third-quarter results that beat Wall Street forecasts. The company earned $15.8 million, or 61 cents a share, on sales of $33 million. Analysts polled by Thomson First Call expected earnings of 49 cents a share and sales of $32.4 million. Last year, United Therapeutics earned $6.3 million, or 27 cents a share, in the third quarter, on sales of $20 million. The company attributed the improved results to expanded sales of its drug Remodulin, which treats high blood pressure. Shares were trading up $6.38 to $73.48. Integra LifeSciences ( IART) fell 5% after the company posted mixed third-quarter results and forecast fourth-quarter sales below analysts' average expectation. The medical device maker reported earnings of $10.5 million, or 33 cents a share, for the third quarter. Excluding items, the company would have earned $11.5 million, or 36 cents a share, beating analysts' mean estimate by 2 cents a share. However, the company posted sales of $69.3 million, below Wall Street's forecast of $72.6 million. For the year-earlier period, Integra posted adjusted earnings of $8.6 million, or 26 cents a share, on sales of $59.1 million. For the fourth quarter, Integra forecast adjusted earnings, which exclude items, of 36 cents to 40 cents a share, compared with analysts' projection of 40 cents. The company sees sales of $71 million to $74 million, below analysts' expectation of $78.1 million. For 2006, the company continues to expect earnings of $1.65 to $1.75 a share. Sales, meanwhile, are expected to be between $330 million and $340 million. Analysts predict 2006 earnings of $1.67 a share and sales of $346.7 million. Integra shares were trading down $1.90 to $34.03. Shares of DaVita ( DVA) rose 3% after the company reported third-quarter earnings per share that beat expectations by a penny. The operator of dialysis centers earned $55.2 million, or 53 cents a share, on sales of $676.8 million. Analysts were expecting earnings of 52 cents a share and sales of $701.8 million. A year earlier, DaVita earned $60.4 million, or 59 cents a share, on sales of $595.5 million. Shares recently gained $1.32 to $49.31.
NeoPharm ( NEOL) rose 4% after the company said it hired Guillermo Herrera as its new chief executive. Herrera, 52, will take over for Ronald Eidell, who had served as interim CEO during the past eight months. Herrera, who worked at Abbott Laboratories ( ABT) for 24 years, most recently served as senior vice president of international operations and president of Abbott International. NeoPharm shares were trading up 37 cents to $9.43. Other health care volume movers included Pfizer ( PFE), up 17 cents to $21.67; Novavax ( NVAX), up 33 cents to $3.92; Chiron ( CHIR), up 80 cents to $44.20; Johnson & Johnson ( JNJ), down 20 cents to $62.75; Teva Pharmaceutical ( TEVA), up 65 cents to $37.94; Amgen ( AMGN), unchanged at $75.78; Merck ( MRK), up 39 cents to $27.93; Schering-Plough ( SGP), down 12 cents to $20.21; and Genentech ( DNA), up $2.62 to $90.34.